非小细胞肺癌中BCL-2、P53蛋白的表达及其意义  

Expression and clinical significances of BCL-2 and P53 in non-small cell lung cancer

作　　者：曹焱[1] 地力木腊提.托乎提 

机构地区：[1]阿克苏地区第一人民医院肿瘤科,新疆阿克苏843000

出　　处：《新疆医科大学学报》2011年第6期588-590,共3页Journal of Xinjiang Medical University

摘　　要：目的 探讨BCL-2、P53蛋白在非小细胞肺癌中的表达及其意义。方法采用免疫组化SP法检测60例非小细胞肺癌和10例肺良性病变组织中BCL-2、P53蛋白的表达。结果非小细胞肺癌BCL-2蛋白阳性表达率（51.7%）明显高于肺良性病变组织（10.0%）（P〈0.05）;非小细胞癌临床Ⅲ~Ⅳ期的表达率（54.3%）与Ⅰ~Ⅱ期的表达率（48.0%）差异无统计学意义（P〉0.05）。非小细胞肺癌中P53蛋白阳性表达率为56.7%,肺良性病变组织中未见P53蛋白表达,差异有统计学意义（P〈0.05）;P53蛋白在临床Ⅲ~Ⅳ期非小细胞肺癌中阳性表达率（71.4%）显著高于Ⅰ~Ⅱ期的阳性表达率（36.0%）（P〈0.05）。结论联合检测BCL-2蛋白和P53蛋白可提高肺癌的早期诊断率,对判断病情及预后有重要临床意义。Objective To investigate the expression and its significance of P53 and BCL-2 in non-small cell lung cancer（NSCLC）.Methods The expression of P53 and BCL-2 was evaluated in 60 specimens of NSCLC and 10 specimens benign lung tissues by immunohistochemistry S-P method.Results The positive rate of BCL-2 in NSCLC was（51.7%）,which was significantly higher than that of BCL-2 in benign tissues（0.0%）（P0.05）;But no statistically significant difference was found between clinical stage Ⅰ~Ⅱ（48.0%） and clinical stage Ⅲ~Ⅳ（54.3%）（P0.05）.The positive rate of P53 in NSCLC was（56.7%）,which was significantly higher than that of P53 in benign tissues（0.0%）（P0.05）;The positive rate of P53 in clinical stage Ⅲ~Ⅳ NSCLC（71.4%） was significantly higher than that in stage Ⅰ~Ⅱ（36.0%）（P0.05）.Conclusion The BCL-2 and P53 gene may participate in carcinogenesis and development of lung cancer and it could be identified as a marker to diagnosis and prognosis of it.

关 键 词：非小细胞肺癌 P53 BCL-2 免疫组织化学 

分 类 号：R34[医药卫生—基础医学] R734.2